Schonfeld Strategic Advisors LLC Takes Position in argenx SE (NASDAQ:ARGX)

Schonfeld Strategic Advisors LLC purchased a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 5,368 shares of the company's stock, valued at approximately $3,301,000.

A number of other institutional investors have also recently bought and sold shares of the stock. FMR LLC boosted its holdings in shares of argenx by 17.2% in the fourth quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after buying an additional 824,750 shares during the period. Capital World Investors grew its position in argenx by 5.1% during the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock worth $1,099,002,000 after purchasing an additional 86,687 shares in the last quarter. Clearbridge Investments LLC raised its stake in argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock valued at $387,344,000 after purchasing an additional 40,330 shares during the period. Jennison Associates LLC lifted its holdings in shares of argenx by 27.0% in the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock valued at $185,821,000 after purchasing an additional 64,183 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in shares of argenx by 26.5% in the fourth quarter. Lord Abbett & CO. LLC now owns 206,202 shares of the company's stock worth $126,814,000 after buying an additional 43,239 shares during the period. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenx Stock Performance

Shares of NASDAQ:ARGX traded down $41.54 during trading on Tuesday, hitting $615.11. 476,926 shares of the stock were exchanged, compared to its average volume of 310,514. The company's fifty day simple moving average is $598.80 and its 200-day simple moving average is $612.99. The company has a market capitalization of $37.56 billion, a price-to-earnings ratio of -698.99 and a beta of 0.57. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Oppenheimer increased their price objective on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. JMP Securities raised their price target on shares of argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a report on Tuesday, January 14th. Wells Fargo & Company boosted their price objective on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Truist Financial reissued a "buy" rating and set a $700.00 target price (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, William Blair reiterated an "outperform" rating on shares of argenx in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, argenx has a consensus rating of "Moderate Buy" and a consensus target price of $699.28.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.